


**Claims**

1. A compound of general formula (I):



5

(I)

- wherein  $X_1$  is H or  $COR_1$  and  $X_2$  is H or  $COR_2$  but  $X_1$  and  $X_2$  are not both H;  
 $R_1$  and  $R_2$  are the same or different and are each  $C_{1-4}$  alkyl substituted with  $R_3$ , or a four to seven-membered ring which can be optionally substituted with  $R_8$   
 10 and can contain one or more additional heteroatoms selected from O,  $S(O)_n$  and  $NR_9$ ;

$R_3$  is F,  $CF_3$ ,  $OR_4$ ,  $NR_5R_6$  or  $S(O)_nR_7$ ;

- $R_4$ ,  $R_5$  and  $R_6$  are the same or different and are each H or  $C_{1-4}$  alkyl optionally substituted with  $R_3$ , or  $NR_5R_6$  is a  $C_{4-6}$  heterocycloalkyl ring containing one or more  
 15 heteroatoms selected from O,  $NR_8$  and  $S(O)_n$ ;

each n is 0-2;

$R_7$  is  $C_{1-4}$  alkyl;

$R_8$  is as defined for  $R_3$  or  $C_{1-4}$  alkyl optionally substituted with  $R_3$  or halogen;

and

- 20  $R_9$  is H or  $C_{1-4}$  alkyl;

or a salt, solvate or hydrate thereof.

2. A compound of claim 1, wherein  $X_1$  is  $COR_1$  and  $X_2$  is  $COR_2$ .  
 3. A compound of claim 1, wherein  $X_1$  is H and  $X_2$  is  $COR_2$ .  
 4. A compound of claim 1, wherein  $X_1$  is  $COR_1$  and  $X_2$  is H.  
 25 5. A compound of any preceding claim, wherein  $R_3$  is  $CF_3$ ,  $OR_4$ ,  $NR_5R_6$  or  $S(O)_nR_7$ .  
 6. A compound of claim 1, which is  
 4,5-Bis(tetrahydropyran-4-carbonloxy)-9,10-dioxo-dihydroanthracene-2-carboxylic acid.

7. A compound of claim 1, which is;  
4,5-bisbutyryloxy-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid;  
4,5-bis(2-benzyloxyacetyloxy)-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid;
- 5 4,5-bis(4-methoxybutyryloxy)-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid ; or  
4,5-bis(tetrahydrofuran-3-carbonyloxy)-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid.
8. A pharmaceutical composition for use in therapy, comprising a compound of  
10 any of claims 1 to 7 and a pharmaceutically acceptable diluent or carrier.
9. Use of a compound of any of claims 1 to 7, for the manufacture of a medicament for the treatment or prevention of a condition associated with T-cell proliferation or that is mediated by pro-inflammatory cytokines.
10. Use according to claim 9, wherein the condition is a chronic degenerative  
15 disease such as rheumatoid arthritis, osteoarthritis or osteoporosis.
11. Use according to claim 9, wherein the condition is a chronic demyelinating disease such as multiple sclerosis.
12. Use according to claim 9, wherein the condition is a respiratory disease such as asthma or chronic obstructive pulmonary disease (COPD).
- 20 13. Use according to claim 9, wherein the condition is an inflammatory bowel disease (IBD) such as ulcerative colitis or Crohn's disease.
14. Use according to claim 9, wherein the condition is a dermatological condition such as psoriasis, scleroderma or atopic dermatitis.
15. Use according to claim 9, wherein the condition is a dental disease such as  
25 periodontal disease or gingivitis.
16. Use according to claim 9, wherein the condition is diabetic nephropathy, lupus nephritis, IgA nephropathy or glomerulonephritis.
17. Use according to claim 9, wherein the condition is systemic lupus erythematosus (SLE).
- 30 18. Use according to claim 9, wherein the condition is graft vs host disease.